Update on aurora kinase targeted therapeutics in oncology

Bibliography

• World cancer report, 2008. Available from: http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/wcr_2008.pdf [Accessed 8 October 2010]
   Google Scholar
• The global economic cost of cancer. Available from: http://www.cancer.org/acs/groups/content/@internationalaffairs/documents/document/acspc-026203.pdf [Accessed 8 October 2010]
   Google Scholar
• Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-54
   PubMed Web of Science ®Google Scholar
• Ducat D, Zheng Y. Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res 2004;301:60-7
   PubMed Web of Science ®Google Scholar
• Marumoto T, Zhang D, Saya H. Aurora A, a guardian of poles. Nat Rev Cancer 2005;5:42-50
   PubMed Web of Science ®Google Scholar
• Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5:1-10
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Nakamura S, Ono T, Analysis of aurora kinase expressions and cell cycle regulation by aurora C in leukemia cells. Blood (ASH Annual Meeting Abstracts) 2006;108: abstract 1366
   Google Scholar
• Slattery SD, Mancini MA, Brinkley BR, Hall RM. Aurora-C kinase supports mitotic progression in the absence of aurora-B. Cell Cycle 2009;8:2986-97
   Web of Science ®Google Scholar
• Zhang X. Aurora kinases. Curr Biol 2008;18(4):R146-8
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clin Cancer Res 2006;12(23):6869-75
   PubMed Web of Science ®Google Scholar
• Girdler F, Gascoigne KE, Eyers PA, Validating aurora B as an anti-cancer drug target. J Cell Sci 2006;119(17):3664-75
   PubMed Web of Science ®Google Scholar
• Nishida N, Nagasaka T, Kashiwagi K, High copy amplification of the aurora A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther 2007;6(4):525-33
   PubMed Web of Science ®Google Scholar
• Gritsko TM, Coppola D, Paciga JE, Activation and overexpression of centrosome kinase BTAK/Aurora A in human ovarian cancer. Clin Cancer Res 2003;9:1420-6
   PubMed Web of Science ®Google Scholar
• Anand S, Penrhyn-Lowe S, Venkitaraman AR. Aurora-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol Cancer Cell 2003;3(1):51-62
   Google Scholar
• Karthigeyan D, Prasad SB, Shandilya J, Biology of aurora A kinase: implications in cancer manifestation and therapy. Med Res Rev 2010: published online 1 March 2010, doi: 10.1002/med.20203
   Google Scholar
• Gautschi O, Heighway J, Mack PC, Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14(6):1639-48
   PubMed Web of Science ®Google Scholar
• Ujhazy P, Stewart D. DNA repair. J Thorac Oncol 2009;11(4 Suppl 3):S1068-70
   Google Scholar
• Smith SL, Bowers NL, Betticher DC, Overexpression of aurora B kinase (AURBK) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer 2005;93(6):719-29
   PubMed Web of Science ®Google Scholar
• Keen M, Taylor S. Mitotic drivers – inhibitors of the aurora B kinase. Cancer Metastasis Rev 2009;28:185-95
   PubMed Web of Science ®Google Scholar
• Mountzios G, Terpos E, Dimopoulos M-A. Aurora kinases as targets for cancer therapy. Cancer Treat Rev 2008;34:175-82
   PubMed Web of Science ®Google Scholar
• Mazumdar A, Henderson YC, El-Naggar AK, Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck 2009;31(5):625-34
   PubMed Web of Science ®Google Scholar
• Kretzner L, Scuto A, Claudia K, Combination therapy with the histone deacetylase inhibitor vorinostat plus the novel aurora kinase A inhibitor MK-5108 leads to enhanced lymphoma cell death due to acetylation of p53 and repression of c-Myc, hTERT, and miRNA levels. Blood (ASH Annual Meeting Abstracts) 2009;114: abstract 1690
   Google Scholar
• Bray MR, Fletcher GC, Denny TA, ENMD-981693 is an orally-active kinase inhibitor with activity towards human hematologic cancers in vitro and in vivo. Blood (ASH Annual Meeting Abstracts) 2006;108: abstract 1377
   Google Scholar
• Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res 2010;16(11):2989-98
   PubMed Web of Science ®Google Scholar
• Wang X, Sinn AL, Pollok K, Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol 2010;150:313-25
   PubMed Web of Science ®Google Scholar
• Bastos BR, Diamond J, Hansen R, An open-label, dose escalation, safety, and pharmacokinetic study of ENMD-2076 administered orally to patients with advanced cancer. J Clin Oncol 2009;27(15s Suppl): abstract 3520
   Google Scholar
• Wang X, Sinn AL, Suvannasankha A, The novel aurora kinase inhibitor ENMD-2076 has potent single agent activity against multiple myeloma in vitro and in vivo, and shows synergistic activity in combination with lenalidomide. Blood (ASH Annual Meeting Abstracts) 2008;112: abstract 3660
   Google Scholar
• U.S. National Institutes of Health. Available from: www.clinicaltrials.gov [accessed 9 October 2010]
   Google Scholar
• Shimomura T, Hasako S, Nakatsuru Y, MK-5108, a highly selective aurora A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther 2010;9(1):157-66
   PubMed Web of Science ®Google Scholar
• Minton SE, LoRusso P, Lockhart AC, A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors. J Clin Oncol 2010;28(15s Suppl): abstract e13026
   Google Scholar
• Jones SF, Cohen RB, Dees EC, Phase I clinical trial of MLN8054, a selective inhibitor of aurora A kinase. J Clin Oncol 2007;25(18s Suppl): abstract 3577
   Google Scholar
• Manfredi MG, Ecsedy JA, Meetze KA, Antitumor activity of MLN8054, an orally active small-molecule inhibitor of aurora A kinase. Proc Natl Acad Sci 2007;104:4106-11
   PubMed Web of Science ®Google Scholar
• Hoar K, Chakravarty A, Rabino C, MLN8054, a small-molecule inhibitor of aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 2007;27(12):4513-25
   PubMed Web of Science ®Google Scholar
• Galvin KM, Huck J, Burenkova O, Preclinical pharmacodynamic studies of aurora A inhibition by MLN8054. J Clin Oncol 2006;24(18s Suppl): abstract 13059
   Google Scholar
• Huck J, Zhang M, Burenkova O, Preclinical antitumor activity with MLN8054, a small molecule aurora A kinase inhibitor. Proc Amer Assoc Cancer Res 2006;47: abstract 4698
   Google Scholar
• Huck J, Zhang M, McDonald A, MLN8054, an inhibitor of aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res 2010;8(3):373-84
   PubMed Web of Science ®Google Scholar
• Dees E, Infante JR, Cohen RB, Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of aurora A kinase [abstract 281]. Eur J Cancer Suppl 2008;6(12):91
   Google Scholar
• Macarulla T, Cervantes A, Elez E, Phase I study of the selective aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther 2010;9(10):2844-52
   PubMed Web of Science ®Google Scholar
• Maris JM, Morton CL, Gorlick R, Initial testing of the aurora kinase A inhibitor MLN8237 by the pediatric preclinical testing program (PPTP). Pediatr Blood Cancer 2010;55:26-34
   PubMed Web of Science ®Google Scholar
• Lipsitz EG, Nhuten V, Zhao H, Modeling MLN8237, an aurora A kinase inhibitor, with irinotecan and temozolomide in neuroblastoma. J Clin Oncol 2010;28(15s Suppl): abstract 10593
   Google Scholar
• Huck JJ, Zhang M, Hyper ML, Manfredi MG. Anti-tumor activity of the aurora A inhibitor MLN8237 in diffuse large B-cell lymphoma preclinical model. Blood (ASH Annual Meeting Abstracts) 2008;112: abstract 1592
   Google Scholar
• Zhang M, Huck J, Sells T, In vivo characterization of the aurora A kinase inhibitor MLN8237 in subcutaneous and disseminated models of human cancer. Proc Am Assoc Cancer Res 2008;49: abstract 5646
   Google Scholar
• Nawrocki ST, Medina E, Smith S, The aurora kinase inhibitor MLN8237 has potent anticancer activity in CML and Ph+ ALL models and significantly increases the efficacy of nilotinib. Blood (ASH Annual Meeting Abstracts) 2008;112: abstract 3198
   Google Scholar
• Gorgun G, Calabrese E, Hideshima T, A novel aurora-A kinase inhibitor MLN-8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010;115(25):5202-13
   PubMed Web of Science ®Google Scholar
• Kelly KR, Swords RT, Mahalingam D, The novel orally active aurora A kinase inhibitor MLN8237 is highly active in preclinical models of acute myeloid leukemia and significantly increases the efficacy of cytarabine. Blood (ASH Annual Meeting Abstracts) 2009;114: abstract 2087
   Google Scholar
• Huck J, Zhang M, Hyer M, Antitumor activity of the aurora A inhibitor MLN8237 in combination with docetaxel in xenograft models of breast and prostate cancer. Proc Am Assoc Cancer Res 2009;50: abstract 3724
   Google Scholar
• Infante J, Dees EC, Cohen RB, Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective aurora A kinase inhibitor, in the United States [abstract 280]. Eur J Cancer Suppl 2008;6(12):90
   Google Scholar
• Cervantes-Ruiperez A, Elez ME, Rosello S, Phase I pharmacokinetic and pharmacodynamic study of MLN8237, a novel selective aurora A kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2009;27(15s suppl): abstracat 2565
   Google Scholar
• Dees EC, Infante JR, Burris HA, Phase I study of the investigational drug MLN8237, an aurora A kinase inhibitor, in patients with solid tumors. J Clin Oncol 2010;28(15s suppl): abstract 3010
   Google Scholar
• Cervantes-Ruiperez, Burris HA, Cohen RB, Pharmacokinetic and pharmacodynamic results from two phase I studies of the investigational selective aurora A kinase (AAK) inhibitor MLN8237: exposure-dependent AAK inhibition in human tumors. J Clin Oncol 2010;28(15s Suppl): abstract 3031
   Google Scholar
• Mosse YP, Lipsitz EG, Maris JM, A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora A kinase: A Children's Oncology Group Phase I Consortium study. J Clin Oncol 2010;28(15s Suppl): abstract 9529
   Google Scholar
• Shah NP, Kasap C, Paquette R, Targeting drug-resistant CML and Ph+ ALL with the spectrum selective protein kinase inhibitor XL-228. Blood (ASH Annual Meeting Abstracts) 2007;110: abstract 474
   Google Scholar
• Cortes J, Paquette R, Talpaz M, Preliminary clinical activity in a phase I trial of the BCR-Abl/IGF-1R/aurora kinase inhibitor XL-228 in patients with Ph+ leukemias with either failure to multiple TKI therapies or with T315I mutations. Blood (ASH Annual Meeting Abstracts) 2008;112: abstract 3232
   Google Scholar
• Smith DC, Britten C, Garon EB, A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients with solid tumors or multiple myeloma. J Clin Oncol 2010;28(15s Suppl): abstract 3105
   Google Scholar
• Shiotsu Y, Kiyoi H, Ozeki K, KW-2449, a novel multi-kinase inhibitor against FLT33, Abl, FGFR1 and aurora, suppresses the growth of AML both in vitro and in vivo. Blood (ASH Annual Meeting abstracts) 2007;110: abstract 1832
   Google Scholar
• Cortes J, Roboz GJ, Kantarjian HM, A phase I dose escalation study of KW-2449, an oral multi-kinase inhibitor against FLT3, Abl, FGFR1 and aurora in patients with relapsed/refractory AML, ALL and MDS or resistant/intolerant CML. Blood (ASH Annual Meeting Abstracts) 2008;112: abstract 2967
   Google Scholar
• Gurtler U, Tontsch-Grunt U, Jarvis M, Effect of BI-811283, a novel inhibitor of aurora B kinase, on tumor senescence and apoptosis. J Clin Oncol 2010;28(15s Suppl): abstract e13632
   Google Scholar
• Solca F, Rudolph D, Guertler U. Targeting the M-phase: Focus on PLK-1 and aurora B [Abstracts of the European Lung Cancer Conference]. J Thoracic Oncol 2010;5(5 Suppl): abstract 28IN
   Google Scholar
• Mross KB, Scheulen ME, Frost A, A phase I dose-escalation study of BI-811283, an aurora B inhibitor, administered every three weeks in patients with advanced solid tumors. J Clin Oncol 2010;28(15s Suppl): abstract 3011
   Google Scholar
• Scheulen ME, Mross KB, Richly H, A phase I dose-escalation study of BI-811283, an aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors. J Clin Oncol 2010;28(15s Suppl): abstract e13065)
   Google Scholar
• Gully CP, Zhang F, Chen J, Antineoplastic effects of an aurora B kinase inhibitor in breast cancer. Mol Cancer 2010;9:42-54
   PubMed Web of Science ®Google Scholar
• Azzariti A, Porcelli L, Simone G, Aurora kinase inhibitor AZD1152 inhibits cell growth, induces apoptosis and enhances chemotherapeutics' activity in various cancer in vitro models. Proc Am Assoc Cancer Res 2007;48: abstract 4359
   Google Scholar
• Wilkinson RW, Keen N, Odedra R, AZD1152: a highly potent and specific aurora kinase inhibitor. Proc Am Assoc Cancer Res 2006;47: abstract 5673
   Google Scholar
• Wilkinson RW, Odedra R, Heaton SP, AZD1152, a selective inhibitor of aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007;13(12):3682-8
   PubMed Web of Science ®Google Scholar
• Goodlad RA, Alferez D, Ryan A, Targeting aurora B kinase activity with AZD1152 leads to antitumor effects in preclinical models of intestinal cancer. Proc Am Assoc Cancer Res 2007;48: abstract 1640
   Google Scholar
• Nair J, Schwartz G. A selective aurora B kinase inhibitor with potent anticancer activity either as a single agent or in combination with irinotecan (CPT-11) in colon cancer cells. Proc Am Assoc Cancer Res 2008;49: abstract 5645
   Google Scholar
• Helfrich B, Theodoro M, Varella-Garcia M, The selective aurora B kinase inhibitor AZD1152-HQPA inhibits in vitro growth of small cell lung cancer cell lines. Proc Am Assoc Cancer Res 2009;50: abstract 4775
   Google Scholar
• Aihara A, Tanaka S, Yasen M, The selective aurora B kinase inhibitor AZD-1152 as a novel treatment for hepatocellular carcinoma. J Hepatol 2010;52:63-71
   PubMed Web of Science ®Google Scholar
• Betta P, Bensi T, Trincheri NF, Aurora B kinase and malignant mesothelioma. J Clin Oncol 2010;28(15s Suppl): abstract e21021
   Google Scholar
• Oke A, Pearce D, Wilkinson RW, AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res 2009;69(1):4150-8
   PubMedGoogle Scholar
• Walsby E, Walsh V, Pepper C, The aurora kinase inhibitor AZD1152 causes perturbation of cell cycle distribution in cell lines and primary AML samples. Blood (ASH Annual Meeting Abstracts) 2005;106: abstract 2759
   Google Scholar
• Pearce D, Odedra R, Wilkinson R, Bonnet D. The specific aurora kinase inhibitor AZD1152 significantly affects the growth of human leukaemic cells in an in vivo AML model. Blood (ASH Annual Meeting Abstracts) 2006;108: abstract 162
   Google Scholar
• Evans RP, Naber C, Steffler T, The selective aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 2007;140:295-302
   PubMed Web of Science ®Google Scholar
• Grundy M, Seedhouse C, Shang S, The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD-1152-HQPA in acute myelogenous leukemia cells. Mol Cancer Ther 2010;9(3):661-72
   PubMed Web of Science ®Google Scholar
• Yang J, Ikezoe R, Nichioka C, AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007;110:2034-40
   PubMed Web of Science ®Google Scholar
• Tao Y, Leteur C, Calderaro J, The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle 2009;8(19):3172-81
   PubMed Web of Science ®Google Scholar
• Walsby E, Walsh V, Pepper C, Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 2008;93(5):662-9
   PubMed Web of Science ®Google Scholar
• Schellens JH, Boss D, Witteveen PO, Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. J Clin Oncol 2006;24(18s Suppl): abstract 3008
   Google Scholar
• Lowenberg B, Rousselot P, Martinelli G, Phase I/II study to assess the safety and efficacy of the aurora B kinase inhibitor, AZD1152, in patients with advanced acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2009;114: abstract 2080
   Google Scholar
• Guo J, Anderson MG, Tapang P, Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD-1152. Pharmacogenomics J 2009;9:90-102
   PubMed Web of Science ®Google Scholar
• Anderson K, Lai Z, McDonald OB, Biochemical characterization of GSK1070916, a potent and selective inhibitor of aurora B and aurora C kinases with an extremely long residence time. Biochem J 2009;420:259-65
   PubMed Web of Science ®Google Scholar
• Hardwicke MA, Oleykowski CA, Plant R, GSK1070916, a potent aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther 2009;8(7):1808-17
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Beeck S. Aurora kinase targeted therapeutics in oncology: past, present and future. Expert Opin Drug Discov 2007;2(7):1011-26
   PubMed Web of Science ®Google Scholar
• Gadea BB, Ruderman JV. Aurora kinase inhibitor ZM447439 blocks chromosome induced spindle assembly, the completion of chromosome condensations, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts. Mol Biol Cell 2005;16:1305-18
   PubMed Web of Science ®Google Scholar
• Ikezoe T, Nichioka C, Tasaka T, ZM447439, a novel aurora kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells. Blood (ASH Annual Meeting Abstracts) 2006;108: abstract 1990
   Google Scholar
• Georgieva I, Koychev D, Wang Y, ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines. Neuroendocrinology 2010;91(2):121-30
   PubMed Web of Science ®Google Scholar
• Vidarsdottir L, Bodvarsdottir S, Ogmundsdottir H, Eyfjord J. Targeting aurora kinases in BRCA2-mutated breast cell lines. Proc Am Assoc Cancer Res 2008;49: abstract 2395
   Google Scholar
• Crispi S, Fagliarone C, Biroccio A, Antiproliferative effect of aurora kinase targeting in mesothelioma. Lung Cancer 2010;70:271-9
   PubMed Web of Science ®Google Scholar
• Emanuel S, Rugg CA, Gruninger RH, The in vitro and in vivo effects of JNJ-7706621: A dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res 2005;65(19):9038-46
   PubMed Web of Science ®Google Scholar
• Howard S, Berdini V, Boulstridge JA, Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009;52:379-88
   PubMed Web of Science ®Google Scholar
• Curry J, Angove H, Fazal L, Aurora B kinase inhibition in mitosis: strategies for optimizing the use of aurora kinase inhibitors such as AT9283. Cell Cycle 2009;8(12):1921-9
   PubMed Web of Science ®Google Scholar
• Dawson MA, Curry JE, Barber K, AT9283, a potent inhibitor of the aurora kinases and JAK2, has therapeutic potential in myeloproliferative disorders. Br J Haematol 2010;150:46-57
   PubMed Web of Science ®Google Scholar
• Squires M, Reule M, Curry J, AT9283, a potent inhibitor of BCR-Abl T315I, is active in CML models. Proc Am Assoc Cancer Res 2008;49: abstract 2820
   Google Scholar
• Goodall J, Squires MS, Lock V, Outcome of aurora kinase inhibition of acute myeloid leukemia by AT9283 is dependent upon the presence or absence of mutations in type 1 oncogenic kinase signaling pathways. Blood (ASH Annual Meeting Abstracts) 208;112: abstract 1613
   Google Scholar
• Lotfi S, Jayanthan A, Lewis VA, AT9283, a novel aurora kinase/JAK2 inhibitor, demonstrates activity against refractory infant leukemia cells: studies on growth inhibition, biological correlates, drug synergy and effects on leukemia stem-like cells. Blood (ASH Annual Meeting Abstracts) 2009;114: abstract 3078
   Google Scholar
• Santo L, Hideshima T, Nelson EA, AT9283, a small molecule multi-targeted kinase inhibitor induces antimyeloma activity via potent aurora kinase and STAT3 inhibition. Blood (ASH Annual Meeting Abstracts) 2009;114: abstract 3833
   Google Scholar
• Ravandi F, Foran J, Verstovsek S, A phase I trial of AT9283, a multitargeted kinase inhibitor, in patients with refractory hematological malignancies. Blood (ASH Annual Meeting Abstracts) 2007;110: abstract 904
   Google Scholar
• Foran JM, Ravandi F, O'Brien SM, Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia. J Clin Oncol 2008;26(15s Suppl): abstract 2518
   Google Scholar
• Plummer ER, Calvert H, Arkenau H, A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours. J Clin Oncol 2008;26(15s Suppl): abstract 2519
   Google Scholar
• Kristeleit R, Calvert H, Arkenau H, A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol 2009;27(15s Suppl): abstract 2566
   Google Scholar
• Jani JP, Arcari J, Bernardo V, PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther 2010;9(4):883-94
   PubMed Web of Science ®Google Scholar
• Jones SF, Burris HA III, Dumez H, Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advance solid tumors: preliminary results. J Clin Oncol 2008;26(15s Suppl): abstract 2517
   Google Scholar
• Bebbington D, Binch H, Charrier J-D, The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett 2009;19:3586-92
   PubMed Web of Science ®Google Scholar
• Lin YG, Immaneni A, Merritt WM, Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 2008;14(17):5437-446
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Z-F, Chen J, VX680/MK-0457, a potent and selective aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res 2010;2(3):296-308
   PubMedGoogle Scholar
• Arlot-Bonnemains Y, Baldini E, Martin B, Effects of the aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocrine Related Cancer 2008;15:559-68
   PubMed Web of Science ®Google Scholar
• Pan C, Yan M, Yao J, Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells. Oral Oncology 2008;44:639-45
   PubMed Web of Science ®Google Scholar
• Cheetham GMT, Charlton PA, Golec JMC, Pollard JR. Structural basis for potent inhibition of the aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett 2007;251:323-9
   PubMed Web of Science ®Google Scholar
• Donato NJ, Fang D, Sun H, Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. Biochem Pharmacol 2010;79:688-97
   PubMed Web of Science ®Google Scholar
• Shah NP, Skaggs B, Branford S, The most common dasatinib-resistant BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia are sensitive to VX-680: rationale for early combination kinase inhibitor therapy. Blood (ASH Annual Meeting Abstracts) 2006;108: abstract 2175
   Google Scholar
• Huang X-F, Luo S-K, Xu J, Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in aurora-A-high acute myeloid leukemia. Blood 2008;111:2854-65
   PubMed Web of Science ®Google Scholar
• Hose D, Reme T, Meissner T, Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 2009;113:4331-40
   PubMed Web of Science ®Google Scholar
• Fiskus W, Wang Y, Joshi R, Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res 2008;14(19):6106-15
   PubMed Web of Science ®Google Scholar
• Harrington EA, Bebbington D, Moore J, VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10(3):262-7
   PubMed Web of Science ®Google Scholar
• Dai Y, Chen S, Venditti CA, Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood 2008;112:793-804
   PubMed Web of Science ®Google Scholar
• Okabe S, Tauchi T, Ohyashiki K. Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. Ann Hematol 2010;89:1081-7
   PubMed Web of Science ®Google Scholar
• Samuel TA, Fiskus W, Wang Y, Novel aurora kinases-targeted combination therapy for breast cancers. J Clin Oncol 2008;26(15s Suppl): abstract 14569
   Google Scholar
• Hoover RR, Harding MW. Synergistic activity of the aurora kinase inhibitor MK-0457 (VX-680) with idarubicin, Ara-C, and inhibitors of BCR-Abl. Blood (ASH Annual Meeting Abstracts) 2006;108: abstract 1384
   Google Scholar
• Hoover RR, Harding MW. Activity of the aurora kinase inhibitor MK-0457 (VX-680) in combination with taxotere. J Clin Oncol 2007;25(18s Suppl): abstract 14069
   Google Scholar
• Hoover RR, Furey B, Pollard J, Harding M. Synergistic activity of the aurora kinase inhibitor MK-0457 (VX-680) with erlotinib. Proc Am Assoc Cancer Res 2008;49: abstract 4016
   Google Scholar
• Tibes R, Giles F, McQueen T, Translational in vivo and in vitro studies in patients with acute myeloid leukemia, chronic myeloid leukemia and myeloproliferative disease treated with MK-0457, a novel aurora kinase, FLT3, JAK2, and BCR-Abl inhibitor. Blood (ASH Annual Meeting Abstracts) 2006;108: abstract 1362
   Google Scholar
• Giles F, Cortes J, Bergstrom DA, MK-0457, a novel multikinase inhibitor, is active in patients with chronic myeloid leukemia and acute lymphocytic leukemia with the T315I BCR-Abl resistance mutation and patients with refractory JAK2-positive myeloproliferative diseases. Blood (ASH Annual Meeting Abstracts) 2006;108: abstract 253
   Google Scholar
• Papayannidis C, Iacobucci I, Soverini S, Innovative phase I study of concomitant and consecutive treatment with dasatinib and MK-0457 in refractory Ph+ CML and ALL patients. J Clin Oncol 2009;27(15s Suppl): abstract 7080
   PubMedGoogle Scholar
• Fancelli D, Moll J, Varasi M, 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent aurora kinase inhibitor with favorable antitumor kinase inhibition profile. J Med Chem 2006;49:7247-51
   PubMed Web of Science ®Google Scholar
• Carpinelli P, Ceruti R, Giorgini ML, PHA-739358, a potent inhibitor of aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6(12):3158-68
   PubMed Web of Science ®Google Scholar
• Benten D, Keller G, Quaas A, Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 2009;11(9):934-44
   PubMed Web of Science ®Google Scholar
• Gontarewicz A, Balabanov S, Keller G, Simultaneous targeting of aurora kinases and BCR-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-Abl mutations including T315I. Blood 2008;111:4355-64
   PubMed Web of Science ®Google Scholar
• Steeghs N, Eskens F, Gelderblom H, Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol 2009;27:5094-101
   PubMed Web of Science ®Google Scholar
• Cohen RB, Jones SF, Aggarwal C, A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009;15(21):6694-701
   PubMed Web of Science ®Google Scholar
• Cortes-Franco J, Dombret H, Schafhausen P, Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts) 2009;114: abstract 864
   Google Scholar
• Hajduch M, Vydra D, Dzubak P, In vivo mode of action of CYC116, a novel small molecule inhibitor of aurora kinases and VEGFR2. Proc Am Assoc Cancer Res 2008;49: abstract 5645
   Google Scholar
• Griffiths G, Scaerou F, Midgley C, Anti-tumor activity of CYC116, a novel small molecule inhibitor of aurora kinases and VEGFR2. Proc Am Assoc Cancer Res 2008;49: abstract 5644
   Google Scholar
• Maccallum D, Melville J, Campbell K, Green S. Combination studies with the oral aurora kinase inhibitor CYC116 and chemotherapeutic agents. Proc Am Assoc Cancer Res 2008;49: abstract 4015
   Google Scholar
• Leteur C, Tao Y, Deutsch E, Bourhis J. Enhancement of radiation response by the aurora kinase inhibitor CYC116 in Ras mutant and p53-deficienct cancer cells. Proc Am Assoc Cancer Res 2009;50: abstract 2481
   Google Scholar
• Oslob JD, Romanowski MJ, Allen DA, Discovery of a potent and selective aurora kinase inhibitor. Bioorg Med Chem Lett 2008;18:4880-4
   PubMed Web of Science ®Google Scholar
• Arbitrario JP, Belmont BJ, Evanchik MJ, SNS-314, a pan-aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol 2010;65:707-17
   PubMed Web of Science ®Google Scholar
• VanderPorten EC, Taverna P, Hogan JN, The aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther 2009;8(4):930-9
   PubMed Web of Science ®Google Scholar
• Robert F, Verschraegen C, Hurwitz H, A phase I trial of SNS-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients. J Clin Oncol 2009;27(15s Suppl): abstract 2536
   Google Scholar
• Payton M, Bush TL, Chung G, Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 2010;70(23):9846-54
   PubMed Web of Science ®Google Scholar
• Akahane D, Tauchi T, Okabe S, Activity of a novel aurora kinase inhibitor against the T315I mutant form of BCR-Abl: in vitro and in vivo studies. Cancer Sci 2008;99:1251-7
   PubMed Web of Science ®Google Scholar
• Evans R, Naber C, Steffler R, Aurora A kinase RNAi and small molecule inhibition of aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk Lymphoma 2008;49(3):559-69
   PubMed Web of Science ®Google Scholar
• Lin Z-Z, Hsu H-C, Hsu C-H, The aurora kinase inhibitor VE-465 has anticancer effects in preclinical studies of human hepatocellular carcinoma. J Hepatol 2009;50:518-27
   PubMed Web of Science ®Google Scholar
• Scharer CD, Laycock N, Osunkoya AO, Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med 2008;6:79-91
   PubMedGoogle Scholar
• Ohmine K, Nagai T, Yoshida K, Vincristine potentiates the anti-leukemia effect of the aurora kinase inhibitor VE-465 by enhancing apoptosis in myeloid leukemia cells. Blood (ASH Annual Meeting Abstracts) 2009;114: abstract 2762
   Google Scholar
• McLaughlin J, Markovtsov V, Li H, Preclinical characterization of the aurora kinase inhibitor R763/AS703569 identified through image-based phenotypic screen. J Cancer Res Clin Oncol 2010;136:99-113
   PubMed Web of Science ®Google Scholar
• Sarno S, Shaw J, Spooner E, The novel aurora kinase inhibitor AS703569 shows potent anti-tumor activity in acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2007;110: abstract 915
   Google Scholar
• Delmore J, Cervi DN, McMillin D, The transcriptional signature of kinases inhibited by the multi-targeted kinase inhibitor AS703569 is associated with clinical outcome in multiple myeloma (MM): anti-MM activity of AS703569 in preclinical studies. Blood (ASH Annual Meeting Abstracts) 2009;114: abstract 730
   Google Scholar
• Renshaw JS, Patnaik A, Gordon M, A phase I two arm trial of AS703569 (R763), an orally available aurora kinase inhibitor, in subjects with solid tumors: preliminary results. J Clin Oncol 2007;25(18s Suppl): abstract 14130
   Google Scholar
• Sonet A, Graux C, Maertens J, Phase I, dose-escalation study of 2 dosing regimens of AS703569, an inhibitor of aurora and other kinases, administered orally in patients with advanced hematological malignancies. Blood (ASH Annual Meeting Abstracts) 2008;112: abstract 2963
   Google Scholar
• Mahadevan D, Qi W, Cooke L, Targeting aurora kinase in aggressive B-cell non-Hodgkin's lymphomas. Blood (ASH Annual Meeting Abstracts) 2009;114: abstract 284
   Google Scholar
• den Hollander J, Rimpi S, Doherty JR, Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 2010;116(9):1498-505
   PubMed Web of Science ®Google Scholar
• Yang D, Liu H, Goga A, Proc Natl Acad Sci USA 2010;107(31):13836-41
   PubMed Web of Science ®Google Scholar